New Orleans, LA, November 9, 2004 – High levels of an enzyme – lipoprotein-associated phospholipase A2 (Lp-PLA2) – believed to trigger a cascade of inflammatory events in atherosclerosis can ...

Aging and chronic conditions are risk factors for mortality in patients with pneumonia. Lipoprotein-associated phospholipase ...

SNP318, a novel oral Lp-PLA2 inhibitor optimized for CNS diseases, advances into human clinical trials. Systemic administration of oral Lp-PLA2 inhibitors has previously been shown to repair ...

The protein is called, Lp-PLA2, an abbreviation that stands for Lipoprotein-associated phospholipase A2. Lp-PLA2 is produced by inflammatory cells in plaques that build up in arteries. These ...

Lp-PLA2 (lipoprotein associated phospholipase A2) which closely mirrors the plaque activity and the inflammatory changes is a frontrunner among the various vascular inflammatory biomarkers.

Products for Investors All Products and Services ...

Beijing DP Technology Co. Ltd. has nominated DPT-0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a preclinical candidate for the treatment of diabetic ...

With the pharmaceutical-grade mineral oil, there were increases in interleukin-1β (IL-1β), lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), lipoprotein(a), and homocysteine.

BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0415, a novel small molecule targeting Lipoprotein‐associated ...